Motley Fool Wealth Management LLC Increases Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Motley Fool Wealth Management LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 157.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 295,856 shares of the medical device company's stock after acquiring an additional 180,775 shares during the quarter. DexCom makes up 1.0% of Motley Fool Wealth Management LLC's holdings, making the stock its 29th biggest position. Motley Fool Wealth Management LLC owned approximately 0.08% of DexCom worth $19,834,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the second quarter valued at about $25,000. Sachetta LLC boosted its stake in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company's stock valued at $27,000 after acquiring an additional 171 shares during the last quarter. Riverview Trust Co boosted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after acquiring an additional 232 shares during the last quarter. DT Investment Partners LLC lifted its stake in shares of DexCom by 492.2% during the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock valued at $43,000 after buying an additional 315 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom during the 3rd quarter valued at approximately $57,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

Shares of NASDAQ:DXCM traded down $0.09 during trading on Wednesday, reaching $80.82. The company had a trading volume of 1,918,402 shares, compared to its average volume of 3,908,231. The company has a fifty day moving average of $71.83 and a two-hundred day moving average of $86.83. The stock has a market capitalization of $31.57 billion, a P/E ratio of 48.45, a price-to-earnings-growth ratio of 2.43 and a beta of 1.12. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company's stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,431 shares of company stock valued at $399,319 in the last quarter. Insiders own 0.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently commented on DXCM. Piper Sandler restated an "overweight" rating and set a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a research note on Friday, October 25th. Raymond James dropped their price target on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research note on Friday, October 25th. Wells Fargo & Company upped their price target on shares of DexCom from $80.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, October 25th. Finally, StockNews.com cut shares of DexCom from a "buy" rating to a "hold" rating in a research note on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.